1.            Cern, A. et al. Nano-mupirocin as tumor-targeted antibiotic: Physicochemical, immunotoxicological and pharmacokinetic characterization, and effect on gut microbiome. J. Control. Release 373, 713–726 (2024).

2.            Anchordoquy, T. et al. Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions. ACS Nano 18, 13983–13999 (2024).

3.            Chen, B.-M. et al. Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies. ACS Nano (2024) doi:10.1021/acsnano.4c05409.

4.            Szebeni, J. et al. Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes. ACS Nano 17, 13147–13157 (2023).

5.            Chen, W.-A. et al. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines. ACS Nano 17, 5757–5772 (2023).

6.            Bavli, Y. et al. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). J. Control. Release 354, 316–322 (2023).

7.            Shilo-Benjamini, Y. et al. Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis. Front. Vet. Sci. 10, (2023).

8.            Pinto, N. et al. Resolvin D1 improves allograft osteointegration and directly enhances osteoblasts differentiation. Front. Immunol. 14, (2023).

9.            Klein, Y. et al. Resolvin D1 shows osseous-protection via RANK reduction on monocytes during orthodontic tooth movement. Front. Immunol. 13, (2022).

10.          Shilo-Benjamini, Y. et al. A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog. Front. Vet. Sci. 9, (2022).

11.          Saragovi, A. et al. Analysis of cellular water content in T cells reveals a switch from slow metabolic water gain to rapid water influx prior to cell division. J. Biol. Chem. 298, (2022).

12.          Szebeni, J. et al. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nat. Nanotechnol. 17, 337–346 (2022).

13.          Chaushu, S., Klein, Y., Mandelboim, O., Barenholz, Y. & Fleissig, O. Immune Changes Induced by Orthodontic Forces: A Critical Review. J. Dent. Res. 101, 11–20 (2022).

14.          Cern, A. et al. Therapeutic potential of injectable nano-mupirocin liposomes for infections involving multidrug-resistant bacteria. Pharmaceutics 13, (2021).

15.          Portnoy, E. G., Andriyanov, A. V, Han, H., Eyal, S. & Barenholz, Y. Pegylated liposomes remotely loaded with the combination of doxorubicin, quinine, and indocyanine green enable successful treatment of multidrug-resistant tumors. Pharmaceutics 13, (2021).

16.          Goldstein, Y. et al. Breaking the third wall: Implementing 3d-printing technics to expand the complexity and abilities of multi-organ-on-a-chip devices. Micromachines 12, (2021).

17.          Schilt, Y. et al. Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs. Biochim. Biophys. Acta - Gen. Subj. 1865, (2021).

18.          Szebeni, J. & Barenholz, Y. C. Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Effects of Liposomes. in Advances in Clinical Immunology, Medical Microbiology, COVID-19, and Big Data 55–75 (Jenny Stanford Publishing, 2021).

19.          Bavli, Y., Rabie, M., Fellig, Y., Nevo, Y. & Barenholz, Y. Liposomal bupivacaine (Bupigel) demonstrates minimal local nerve toxicity in a rabbit functional model. Pharmaceutics 13, 1–17 (2021).

20.          Nordström, R. et al. Quantitative cryo-tem reveals new structural details of doxil-like pegylated liposomal doxorubicin formulation. Pharmaceutics 13, 1–19 (2021).

21.          Klein, Y. et al. Immunorthodontics: in vivo gene expression of orthodontic tooth movement. Sci. Rep. 10, (2020).

22.          Chen, E. et al. Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex. ACS Nano 14, 7808–7822 (2020).

23.          Bavli, Y. et al. PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A correlation between in vitro immunological and in vivo clinical studies. Molecules 25, (2020).

24.          Singh, M. S. et al. An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. Nanoscale 12, 1894–1903 (2020).

25.          Silverman, L. & Barenholz, Y. Effect of major tumor metabolites on the release of doxorubicin from Doxil – implications for precision nanomedicine. Precis. Nanomedicine 3, 699–708 (2020).

26.          Even-Or, O., Avniel-Polak, S., Barenholz, Y. & Nussbaum, G. The cationic liposome CCS/C adjuvant induces immunity to influenza independently of the adaptor protein MyD88. Hum. Vaccines Immunother. 16, 3146–3154 (2020).

27.          Gawne, P. J. et al. PET imaging of liposomal glucocorticoids using 89Zr-oxine: Theranostic applications in inflammatory arthritis. Theranostics 10, 3867–3879 (2020).

28.          Goldmann, O. et al. Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections. J. Control. Release 316, 292–301 (2019).

29.          Shaltiel, L., Shemesh, A., Raviv, U., Barenholz, Y. & Levi-Kalisman, Y. Synthesis and Characterization of Thiolate-Protected Gold Nanoparticles of Controlled Diameter. J. Phys. Chem. C 123, 28486–28493 (2019).

30.          Kozma, G. T. et al. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. ACS Nano 13, 9315–9324 (2019).

31.          Bavli, Y. et al. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. J. Control. Release 306, 138–148 (2019).

32.          Abdelrehim, A. et al. The use of tail-anchored protein chimeras to enhance liposomal cargo delivery. PLoS One 14, (2019).

33.          Turjeman, K. et al. Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy. Nanomedicine Nanotechnology, Biol. Med. 16, 34–44 (2019).

34.          Szebeni, J., Simberg, D., González-Fernández, Á., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).

35.          Peretz Damari, S. et al. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes. Int. J. Pharm. 547, 648–655 (2018).

36.          Cern, A., Connolly, K. L., Jerse, A. E. & Barenholz, Y. In vitro susceptibility of neisseria gonorrhoeae strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes. Antimicrob. Agents Chemother. 62, (2018).

37.          Wei, X. et al. Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance. ACS Omega 3, 2508–2517 (2018).

38.          Neun, B. W., Barenholz, Y., Szebeni, J. & Dobrovolskaia, M. A. Understanding the role of anti-PEG antibodies in the complement activation by Doxil in vitro. Molecules 23, (2018).

39.          Mészáros, T. et al. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: Unique surface properties underlying alternative pathway activation and instant opsonization. Int. J. Nanomedicine 13, 6345–6357 (2018).

40.          Barenholz, Y. & Lasic, D. D. Handbook of nonmedical applications of liposomes: Volume III: From design to microreactors. Handbook of Nonmedical Applications of Liposomes: Volume III: From Design to Microreactors (CRC Press, 2018). doi:10.1201/9781351072724.

41.          Barenholz, Y. & Lasic, D. D. General preface. Handb. Nonmedical Appl. Liposomes Vol. III From Des. to Microreactors iii–iv (2018) doi:10.1201/9781351072724.

42.          Barenholz, Y. & Lasic, D. D. Introduction to volume III. Handb. Nonmedical Appl. Liposomes Vol. III From Des. to Microreactors v (2018) doi:10.1201/9781351072724.

43.          Lasic, D. D. & Barenholz, Y. Liposomes in catalysis. in Handbook of Nonmedical Applications of Liposomes: Volume III: From Design to Microreactors 237 (CRC Press, 2018). doi:10.1201/9781351072724.

44.          Lasic, D. D. & Barenholz, Y. Nonlipid llposomes and nonliposomal lipid particles. in Handbook of Nonmedical Applications of Liposomes: Volume III: From Design to Microreactors 95 (CRC Press, 2018). doi:10.1201/9781351072724.

45.          Barenholz, Y. Optimization of amphiphile-based colloidal carriers. in Handbook of Nonmedical Applications of Liposomes: Volume III: From Design to Microreactors 1–3 (CRC Press, 2018). doi:10.1201/9781351072724.

46.          Cedrone, E. et al. Anticoagulants influence the performance of in vitro assays intended for characterization of nanotechnology-based formulations. Molecules 23, (2018).

47.          Barenholz, Y. & Lasic, D. D. An overview of liposome scaled-up production and quality control. in Handbook of Nonmedical Applications of Liposomes: Volume III: From Design to Microreactors 23–30 (CRC Press, 2018). doi:10.1201/9781351072724.

48.          Wei, X. et al. Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy. Mol. Pharm. 14, 4339–4345 (2017).

49.          Andriyanov, A. V et al. Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: Comparing single and combined therapy in young and old mice. J. Control. Release 257, 2–9 (2017).

50.          Cern, A., Marcus, D., Tropsha, A., Barenholz, Y. & Goldblum, A. New drug candidates for liposomal delivery identified by computer modeling of liposomes’ remote loading and leakage. J. Control. Release 252, 18–27 (2017).

51.          Anchordoquy, T. J. et al. Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ACS Nano 11, 12–18 (2017).

52.          Turjeman, K. & Barenholz, Y. Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases. J. Drug Target. 24, 805–820 (2016).

53.          Shmeeda, H. et al. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer. J. Drug Target. 24, 878–889 (2016).

54.          Moallem, E. et al. A liposomal steroid nano-drug for treating systemic lupus erythematosus. Lupus 25, 1209–1216 (2016).

55.          Cern, A. et al. Nano-mupirocin: Enabling the parenteral activity of mupirocin. Eur. J. Nanomedicine 8, 139–149 (2016).

56.          Wei, X., Cohen, R. & Barenholz, Y. Insights into composition/structure/function relationships of Doxil® gained from ‘high-sensitivity’ differential scanning calorimetry. Eur. J. Pharm. Biopharm. 104, 260–270 (2016).

57.          Tinkle, S. et al. Nanomedicines: Addressing the scientific and regulatory gap. in Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety, and Risk vol. 2 413–470 (Pan Stanford Publishing Pte. Ltd., 2016).

58.          Barenholz, Y. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: From the bench to approved doxil. in Liposome Technology: Third Edition vol. 2 1–25 (CRC Press, 2016).

59.          Szebeni, J., Muggia, F. & Barenholz, Y. Case study: complement activation related hypersensitivity reactions to pegylated liposomal doxorubicin - experimental and clinical evidence, mechanisms and approaches to inhibition. in Handbook of Immunological Properties of Engineered Nanomaterials: Second Edition vol. 2 331–361 (World Scientific Publishing Co. Pte. Ltd., 2016).

60.          Barenholz, Y. Doxil®: The first fda-approved nanodrug-from an idea to a product (January 2015 update). in Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications vol. 1 827–906 (Pan Stanford Publishing Pte. Ltd., 2016).

61.          Bawa, R., Barenholz, Y. & Owen, A. The challenge of regulating nanomedicine: Key issues. RSC Drug Discovery Series vols 2016-January 290–314 (2016).

62.          Barenholz, Y. C. Doxils - the first fda-approved nano-drug: From basics via cmc, cell culture and animal studies to clinical use. RSC Drug Discovery Series vols 2016-January 315–345 (2016).

63.          Schilt, Y., Berman, T., Wei, X., Barenholz, Y. & Raviv, U. Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs. Biochim. Biophys. Acta - Gen. Subj. 1860, 108–119 (2016).

64.          Perlstein, H. et al. Thermotropic behavior of celecoxib-loaded beta-casein micelles: Relevance to the improved bioavailability. Eur. J. Nanomedicine 7, 303–312 (2015).

65.          Silverman, L. & Barenholz, Y. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site. Nanomedicine Nanotechnology, Biol. Med. 11, 1841–1850 (2015).

66.          Turovsky, T. et al. Celecoxib Encapsulation in β-Casein Micelles: Structure, Interactions, and Conformation. Langmuir 31, 7183–7192 (2015).

67.          Turjeman, K. et al. Nano-drugs based on nano sterically stabilized liposomes for the treatment of inflammatory neurodegenerative diseases. PLoS One 10, (2015).

68.          Shemi, A., Khvalevsky, E. Z., Gabai, R. M., Domb, A. & Barenholz, Y. Multistep, effective drug distribution within solid tumors. Oncotarget 6, 39564–39577 (2015).

69.          Perlstein, H. et al. Beta-casein nanocarriers of celecoxib for improved oral bioavailability. Eur. J. Nanomedicine 6, 217–226 (2014).

70.          Andriyanov, A. V, Koren, E., Barenholz, Y. & Goldberg, S. N. Therapeutic efficacy of combining PEGylated liposomal doxorubicin and radiofrequency (RF) ablation: Comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes. PLoS One 9, (2014).

71.          Bavli, D., Emanuel, N. & Barenholz, Y. Real-time monitoring of E. coli O157 and Salmonella enterica serovar Typhimurium in water using ultrasound and latex-based immunoassay. Anal. Methods 6, 395–403 (2014).

72.          Guo, J., Waknine-Grinberg, J. H., Mitchell, A. J., Barenholz, Y. & Golenser, J. Reduction of experimental cerebral malaria and its related proinflammatory responses by the novel liposome-based β -methasone nanodrug. Biomed Res. Int. 2014, (2014).

73.          Cern, A., Nativ-Roth, E., Goldblum, A. & Barenholz, Y. Effect of solubilizing agents on mupirocin loading into and release from PEGylated nanoliposomes. J. Pharm. Sci. 103, 2131–2138 (2014).

74.          Tinkle, S. et al. Nanomedicines: Addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences vol. 1313 35–56 (2014).

75.          Cern, A., Barenholz, Y., Tropsha, A. & Goldblum, A. Computer-aided design of liposomal drugs: In silico prediction and experimental validation of drug candidates for liposomal remote loading. J. Control. Release 173, 125–131 (2014).

76.          Cohen, R., Steiner, A., Kanaan, H. & Barenholz, Y. Chemical and physical characterization of remotely loaded bupivacaine liposomes: Comparison between large multivesicular vesicles and small unilamellar vesicles. J. Mater. Chem. B 1, 4619–4627 (2013).

77.          Waknine-Grinberg, J. H. et al. Glucocorticosteroids in Nano-Sterically Stabilized Liposomes Are Efficacious for Elimination of the Acute Symptoms of Experimental Cerebral Malaria. PLoS One 8, (2013).

78.          Regev, O., Barenholz, Y., Peretz, S., Zucker, D. & Bavli-Felsen, Y. Can carbon nanotube-liposome conjugates address the issues associated with carbon nanotubes in drug delivery? Future Med. Chem. 5, 503–505 (2013).

79.          Even-or, O., Samira, S., Ellis, R., Kedar, E. & Barenholz, Y. Adjuvanted influenza vaccines. Expert Rev. Vaccines 12, 1095–1108 (2013).

80.          Cern, A. et al. Quantitative structure - Property relationship modeling of remote liposome loading of drugs. J. Control. Release 160, 147–157 (2012).

81.          Bachar, M. et al. Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. J. Control. Release 160, 164–171 (2012).

82.          Karchemski, F., Zucker, D., Barenholz, Y. & Regev, O. Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells. J. Control. Release 160, 339–345 (2012).

83.          Barenholz, Y. & Peer, D. Liposomes and other assemblies as drugs and nano-drugs: From basic and translational research to the clinics. J. Control. Release 160, 115–116 (2012).

84.          Zucker, D., Andriyanov, A. V, Steiner, A., Raviv, U. & Barenholz, Y. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: Relating structure and pharmacokinetics to therapeutic efficacy. J. Control. Release 160, 281–289 (2012).

85.          Cohen, R., Kanaan, H., Grant, G. J. & Barenholz, Y. Prolonged analgesia from Bupisome and Bupigel formulations: From design and fabrication to improved stability. J. Control. Release 160, 346–352 (2012).

86.          Emanuel, N. et al. A lipid-and-polymer-based novel local drug delivery system - BonyPid TM: From physicochemical aspects to therapy of bacterially infected bones. J. Control. Release 160, 353–361 (2012).

87.          Szebeni, J. et al. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: A porcine model. J. Control. Release 160, 382–387 (2012).

88.          Barenholz, Y. Doxil® - The first FDA-approved nano-drug: Lessons learned. J. Control. Release 160, 117–134 (2012).

89.          Ulmansky, R. et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J. Control. Release 160, 299–305 (2012).

90.          Barenholz, Y. & Peer, D. Liposomes, lipid biophysics, and sphingolipid research: From basic to translation research. Chem. Phys. Lipids 165, 363–364 (2012).

91.          Even-Chen, S., Cohen, R. & Barenholz, Y. Factors affecting DNA binding and stability of association to cationic liposomes. Chem. Phys. Lipids 165, 414–423 (2012).

92.          Szebeni, J. et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: Factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine Nanotechnology, Biol. Med. 8, 176–184 (2012).

93.          Szebeni, J. & Barenholz, Y. C. Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes. in Handbook of Harnessing Biomaterials in Nanomedicine 309–334 (Pan Stanford Publishing Pte. Ltd., 2012). doi:10.4032/9789814364270.

94.          Barenholz, Y. C. Doxil® - The first FDA-approved nano-drug: From an idea to a product. in Handbook of Harnessing Biomaterials in Nanomedicine 335–398 (Pan Stanford Publishing Pte. Ltd., 2012). doi:10.4032/9789814364270.

95.          Emanuel, N. et al. BonyPidTM: A lipid-and-polymer-based novel local drug delivery system Physicochemical aspects and therapy. Eur. Cells Mater. 24, 42 (2012).

96.          Barenholz, Y. & Barenholz, C. Nanomedicine: Shake up the drug containers. Nat. Nanotechnol. 7, 483–484 (2012).

97.          Ostrovsky, L. A., Priev, A., Ponomarev, V. & Barenholz, Y. Acoustic radiation force for rapid detection of particles in biological liquids. in 162nd Meeting Acoustical Society of America 2011 vol. 14 (2011).

98.          Nadler-Milbauer, M. et al. Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. J. Drug Target. 19, 859–873 (2011).

99.          Avnir, Y. et al. Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. PLoS One 6, (2011).

100.        Szebeni, J., Muggia, F., Gabizon, A. & Barenholz, Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention. Adv. Drug Deliv. Rev. 63, 1020–1030 (2011).

101.        Harel, E. et al. Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLoS One 6, (2011).

102.        Goldberg, R. et al. Boundary lubricants with exceptionally low friction coefficients based on 2D close-packed phosphatidylcholine liposomes. Adv. Mater. 23, 3517–3521 (2011).

103.        Goldberg, R., Schroeder, A., Barenholz, Y. & Klein, J. Interactions between adsorbed hydrogenated soy phosphatidylcholine (HSPC) vesicles at physiologically high pressures and salt concentrations. Biophys. J. 100, 2403–2411 (2011).

104.        Barenholz, Y. et al. Influence of lipid composition on the thermotropic behavior and size distribution of mixed cationic liposomes. J. Colloid Interface Sci. 356, 46–53 (2011).

105.        Even-Or, O. et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine 29, 2474–2486 (2011).

106.        Emanuel, N., Segal, D., Rosenfeld, Y., Cohen, O. & Barenholz, Y. The PolyPid - A novel local delivery system: From the physic-chemical aspects to innovative and superior therapeutic potential. Eur. Cells Mater. 21, 17 (2011).

107.        Lahav, J., Herzberg, M., Barenholz, Y. C., Cabilly, S. & Kotler, Y. Vision in venture: angels of innovation. Interviewed by Catarina Wylie. Cell Cycle 10, 1505–1511 (2011).

108.        Priev, A. & Barenholz, Y. Ultrasonic food quality analyzer based on cylindrical standing waves. in 20th International Congress on Acoustics 2010, ICA 2010 - Incorporating the 2010 Annual Conference of the Australian Acoustical Society vol. 4 2708–2711 (2010).

109.        Schroeder, A., Turjeman, K., Schroeder, J. E., Leibergall, M. & Barenholz, Y. Using liposomes to target infection and inflammation induced by foreign body injuries or medical implants. Expert Opin. Drug Deliv. 7, 1175–1189 (2010).

110.        Even-Or, O. et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 28, 6527–6541 (2010).

111.        Zucker, D. & Barenholz, Y. Optimization of vincristine-topotecan combination - Paving the way for improved chemotherapy regimens by nanoliposomes. J. Control. Release 146, 326–333 (2010).

112.        Waknine-Grinberg, J. H. et al. Artemisone effective against murine cerebral malaria. Malar. J. 9, (2010).

113.        Khazanov, E. et al. Specific detection of gastric α-antitrypsin by immobilized trypsin on PolyHEMA films. Mol. Pharm. 7, 944–952 (2010).

114.        Verberne, G., Schroeder, A., Halperin, G., Barenholz, Y. & Etsion, I. Liposomes as potential biolubricant additives for wear reduction in human synovial joints. Wear 268, 1037–1042 (2010).

115.        Sivan, S. et al. Liposomes act as effective biolubricants for friction reduction in human synovial joints. Langmuir 26, 1107–1116 (2010).

116.        Davidson, E. M. et al. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth. Analg. 110, 1018–1023 (2010).

117.        Schroeder, A., Kost, J. & Barenholz, Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem. Phys. Lipids 162, 1–16 (2009).

118.        Zucker, D., Marcus, D., Barenholz, Y. & Goldblum, A. Liposome drugs’ loading efficiency: A working model based on loading conditions and drug’s physicochemical properties. J. Control. Release 139, 73–80 (2009).

119.        Schroedera, A. et al. Surface active phospholipids as cartilage lubricants. in 2008 9th Biennial Conference on Engineering Systems Design and Analysis vol. 3 549–553 (2009).

120.        Kizelsztein, P., Ovadia, H., Garbuzenko, O., Sigal, A. & Barenholz, Y. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J. Neuroimmunol. 213, 20–25 (2009).

121.        Tirosh, B., Khatib, N., Barenholz, Y., Nissan, A. & Rubinstein, A. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol. Pharm. 6, 1083–1091 (2009).

122.        Schroeder, A. et al. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J. Control. Release 137, 63–68 (2009).

123.        Nadler-Milbauer, M., Azab, A. K., Kleinstern, J., Barenholz, Y. & Rubinstein, A. In vitro and in vivo analysis of pulsatile biodegradation of mucoadhesive hydrogels. J. Drug Deliv. Sci. Technol. 19, 247–255 (2009).

124.        Schroeder, A., Sigal, A., Turjeman, K. & Barenholz, Y. Using PEGylated nano-liposomes to target tissue invaded by a foreign body. J. Drug Target. 16, 591–595 (2008).

125.        Khazanov, E., Priev, A., Shillemans, J. P. & Barenholz, Y. Physicochemical and biological characterization of ceramide-containing liposomes: Paving the way to ceramide therapeutic application. Langmuir 24, 6965–6980 (2008).

126.        Shmeeda, H. R., Golden, E. B. & Barenholz, Y. Membrane Lipids and Aging. in Biomembranes, Biomembranes: Structural and Functional Aspects 1–82 (wiley, 2008). doi:10.1002/9783527616114.ch1.

127.        Avnir, Y. et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: A novel approach to treating autoimmune arthritis. Arthritis Rheum. 58, 119–129 (2008).

128.        Boktov, J., Hirsch-Lerner, D. & Barenholz, Y. Characterization of the interplay between the main factors contributing to lipoplex-mediated transfection in cell cultures. J. Gene Med. 9, 884–893 (2007).

129.        Eliyahu, H. et al. Characterization and in vivo performance of dextran-spermine polyplexes and DOTAP/cholesterol lipoplexes administered locally and systemically. Biomaterials 28, 2339–2349 (2007).

130.        Szebeni, J. et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 17, 107–117 (2007).

131.        Schroeder, A. et al. Controlling liposomal drug release with low frequency ultrasound: Mechanism and feasibility. Langmuir 23, 4019–4025 (2007).

132.        Wasserman, V. et al. The antioxidant tempamine: In vitro antitumor and neuroprotective effects and optimization of liposomal encapsulation and release. Langmuir 23, 1937–1947 (2007).

133.        Lichtenberg, D. & Barenholz, Y. Liposomes: Preparation, characterization, and preservation. in Methods of Biochemical Analysis vol. 33 337–462 (John Wiley and Sons Inc., 2006).

134.        Khazanov, E., Simberg, D. & Barenholz, Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J. Gene Med. 8, 998–1007 (2006).

135.        Najajreh, Y. et al. Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies. J. Med. Chem. 49, 4665–4673 (2006).

136.        Najajreh, Y. et al. Interactions of platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with biological nucleophiles. J. Med. Chem. 49, 4674–4683 (2006).

137.        Mitchell, L. A., Joseph, A., Kedar, E., Barenholz, Y. & Galun, E. Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine 24, 5300–5310 (2006).

138.        Joseph, A. et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). I. Immunogenicity and efficacy studies in mice. Vaccine 24, 3990–4006 (2006).

139.        Avnir, Y. & Barenholz, Y. Erratum: pH determination by pyranine: Medium-related artifacts and their correction (Analytical Biochemistry (2005) 347 (34-41) DOI: 10.1016/j.ab.2005. 09.026). Anal. Biochem. 351, 317 (2006).

140.        Jubeh, T. T., Nadler-Milbauer, M., Barenholz, Y. & Rubinstein, A. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J. Drug Target. 14, 155–163 (2006).

141.        Eliyahu, H., Joseph, A., Azzam, T., Barenholz, Y. & Domb, A. J. Dextran-spermine-based polyplexes - Evaluation of transgene expression and of local and systemic toxicity in mice. Biomaterials 27, 1636–1645 (2006).

142.        Eliyahu, H., Siani, S., Azzam, T., Domb, A. J. & Barenholz, Y. Relationships between chemical composition, physical properties and transfection efficiency of polysaccharide-spermine conjugates. Biomaterials 27, 1646–1655 (2006).

143.        Meidan, V. M. et al. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: A comparison between different formulations. J. Liposome Res. 16, 27–43 (2006).

144.        Avnir, Y. & Barenholz, Y. pH determination by pyranine: Medium-related artifacts and their correction. Anal. Biochem. 347, 34–41 (2005).

145.        Simberg, D., Weiss, A. & Barenholz, Y. Reversible mode of binding of serum proteins to DOTAP/cholesterol lipoplexes: A possible explanation for intravenous lipofection efficiency. Hum. Gene Ther. 16, 1087–1096 (2005).

146.        Barenholz, Y. & Yarmut, Y. Enzymatic phospholipid transesterification. Ind. Bioprocess. 27, 8–9 (2005).

147.        Hirsch-Lerner, D. et al. Effect of ‘helper lipid’ on lipoplex electrostatics. Biochim. Biophys. Acta - Biomembr. 1714, 71–84 (2005).

148.        Baru, M. et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb. Haemost. 93, 1061–1068 (2005).

149.        Garbuzenko, O., Barenholz, Y. & Priev, A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem. Phys. Lipids 135, 117–129 (2005).

150.        Najajreh, Y. et al. Structure and unique interactions with DNA of a cationic Trans-platinum complex with the nonplanar bicyclic piperidinopiperidine ligand. Angew. Chemie - Int. Ed. 44, 2885–2887 (2005).

151.        Garbuzenko, O., Zalipsky, S., Qazen, M. & Barenholz, Y. Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir 21, 2560–2568 (2005).

152.        Eliyahu, H. et al. Novel dextran - Spermine conjugates as transfecting agents: Comparing water-soluble and micellar polymers. Gene Ther. 12, 494–503 (2005).

153.        Eliyahu, H., Barenholz, Y. & Domb, A. J. Polymers for DNA delivery. Molecules 10, 34–64 (2005).

154.        Jubeh, T. T., Antler, S., Haupt, S., Barenholz, Y. & Rubinstein, A. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol. Pharm. 2, 2–11 (2005).

155.        Kalmanzon, E., Rahamim, Y., Carmeli, S., Barenholz, Y. & Zlotkin, E. Endogenous regulation of the functional duality of pahutoxin, a marine trunkfish surfactant. Toxicon 44, 939–942 (2004).

156.        Simberg, D., Weisman, S., Talmon, Y. & Barenholz, Y. DOTAP (and other cationic lipids): Chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carrier Syst. 21, 257–317 (2004).

157.        Grant, G. J. et al. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 101, 133–137 (2004).

158.        Jubeh, T. T., Barenholz, Y. & Rubinstein, A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm. Res. 21, 447–453 (2004).

159.        Barenholz, Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell. Biochem. 37, 167–215 (2004).

160.        Samuni, A. M. & Barenholz, Y. Use of nitroxides to protect liposomes against oxidative damage. Methods Enzymol. 387, 299–314 (2004).

161.        Weisman, S., Hirsch-Lerner, D., Barenholz, Y. & Talmon, Y. Nanostructure of cationic lipid-oligonucleotide complexes. Biophys. J. 87, 609–614 (2004).

162.        Simberg, D. et al. The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J. Biol. Chem. 278, 39858–39865 (2003).

163.        Ben-Yehuda, A. et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 21, 3169–3178 (2003).

164.        Gabizon, A., Shmeeda, H. & Barenholz, Y. Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin. Pharmacokinet. 42, 419–436 (2003).

165.        Zvulunov, A., Cagnano, E., Frankenburg, S., Barenholz, Y. & Vardy, D. Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B. Pediatr. Infect. Dis. J. 22, 567–569 (2003).

166.        Barenholz, A. et al. Liposomes enhance bioremediation of oil-contaminated soil. J. Liposome Res. 13, 173–186 (2003).

167.        Barenholz, Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J. Liposome Res. 13, 1–8 (2003).

168.        Ben-Yehuda, A. et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J. Med. Virol. 69, 560–567 (2003).

169.        Samuni, A. M. & Barenholz, Y. Site-activity relationship of nitroxide radical’s antioxidative effect. Free Radic. Biol. Med. 34, 177–185 (2003).

170.        Shmeeda, H. et al. Enzymatic Assays for Quality Control and Pharmacokinetics of Liposome Formulations: Comparison with Nonenzymatic Conventional Methodologies. Methods in Enzymology vol. 367 272–292 (2003).

171.        Kalmanzon, E., Rahamim, Y., Barenholz, Y., Carmeli, S. & Zlotkin, E. Receptor-mediated toxicity of pahutoxin, a marine trunkfish surfactant. Toxicon 42, 63–71 (2003).

172.        Khazanov, E., Barenholz, Y., Gibson, D. & Najajreh, Y. Novel apoptosis-inducing trans-platinum piperidine derivatives: Synthesis and biological characterization. J. Med. Chem. 45, 5196–5204 (2002).

173.        Joseph, A. et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): An efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20, 3342–3354 (2002).

174.        Szebeni, J. et al. Role of complement activation in hypersensitivity reactions to Doxil and HYNIC PEG liposomes: Experimental and clinical studies. J. Liposome Res. 12, 165–172 (2002).

175.        Azzam, T. et al. Polysaccharide-oligoamine based conjugates for gene delivery. J. Med. Chem. 45, 1817–1824 (2002).

176.        Priev, A., Zalipsky, S., Cohen, R. & Barenholz, Y. Determination of critical micelle concentration of lipopolymers and other amphiphiles: Comparison of sound velocity and fluorescent measurements. Langmuir 18, 612–617 (2002).

177.        Azzam, T. et al. Cationic polysaccharides as vectors for gene delivery. in 224th ACS National Meeting vol. 43 671–672 (Polymer Preprints ACS, 2002).

178.        Eliyahu, N., Servel, N., Domb, A. J. & Barenholz, Y. Magnetic properties of iron-containing particles in a quartz matrix after mechanochemical processing. Inorg. Mater. 38, 132–136 (2002).

179.        Shmeeda, H. et al. Heat acclimation in rats: Modulation via lipid polyunsaturation. Am. J. Physiol. - Regul. Integr. Comp. Physiol. 283, R389–R399 (2002).

180.        Eliyahu, N., Servel, N., Domb, A. J. & Barenholz, Y. Lipoplex-induced hemagglutination: Potential involvement in intravenous gene delivery. Gene Ther. 9, 850–858 (2002).

181.        Barenholz, Y. Cholesterol and other membrane active sterols: from membrane evolution to ‘rafts’. Prog. Lipid Res. 41, 1–5 (2002).

182.        Meidan, V. M., Glezer, J., Amariglio, N., Cohen, J. S. & Barenholz, Y. Oligonucleotide lipoplexes: The influence of oligonucleotide composition on complexation. Biochim. Biophys. Acta - Gen. Subj. 1568, 177–182 (2001).

183.        Simberg, D. et al. Phase behavior, DNA ordering, and size instability of cationic lipoplexes: Relevance to optimal transfection activity. J. Biol. Chem. 276, 47453–47459 (2001).

184.        Babai, I. et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine 20, 505–515 (2001).

185.        Grant, G. J. et al. DRV liposomal bupivacaine: Preparation, characterization, and in vivo evaluation in mice. Pharm. Res. 18, 336–343 (2001).

186.        Kerner, M. et al. Interplay in lipoplexes between type of pDNA promoter and lipid composition determines transfection efficiency of human growth hormone in NIH3T3 cells in culture. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1532, 128–136 (2001).

187.        Barenholz, Y. Liposome application: Problems and prospects. Curr. Opin. Colloid Interface Sci. 6, 66–77 (2001).

188.        Szebeni, J. et al. Formation of complement-activating particles in aqueous solutions of Taxol: Possible role in hypersensitivity reactions. Int. Immunopharmacol. 1, 721–735 (2001).

189.        Peleg-Shulman, T., Gibson, D., Cohen, R., Abra, R. & Barenholz, Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta - Biomembr. 1510, 278–291 (2001).

190.        Kalmanzon, E. et al. Cooperative cocktail in a chemical defence mechanism of a trunkfish. Cell. Mol. Biol. Lett. 6, 971–984 (2001).

191.        Vardy, D. et al. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans. R. Soc. Trop. Med. Hyg. 95, 184–186 (2001).

192.        Even-Chen, S. & Barenholz, Y. DOTAP cationic liposomes prefer relaxed over supercoiled plasmids. Biochim. Biophys. Acta - Biomembr. 1509, 176–188 (2000).

193.        Meidan, V. M., Cohen, J. S., Amariglio, N., Hirsch-Lerner, D. & Barenholz, Y. Interaction of oligonucleotides with cationic lipids: The relationship between electrostatics, hydration and state of aggregation. Biochim. Biophys. Acta - Biomembr. 1464, 251–261 (2000).

194.        Samuni, A. M., Lipman, A. & Barenholz, Y. Damage to liposomal lipids: Protection by antioxidants and cholesterol- mediated dehydration. Chem. Phys. Lipids 105, 121–134 (2000).

195.        Kedar, E. et al. Delivery of cytokines by liposomes: Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long- circulating liposomes. J. Immunother. 23, 131–145 (2000).

196.        Kedar, E. et al. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J. Immunother. 23, 4759 (2000).

197.        Barenholz, Y. Liposomology. Prog. Lipid Res. 39, 1–2 (2000).

198.        Simberg, D., Hirsch-Lerner, D., Nissim, R. & Barenholz, Y. Comparison of different commercially available cationic lipid-based transfection kits. J. Liposome Res. 10, 1–13 (2000).

199.        Hirsch-Lerner, D. & Barenholz, Y. Hydration of lipoplexes commonly used in gene delivery: Follow-up by laurdan fluorescence changes and quantification by differential scanning calorimetry. Biochim. Biophys. Acta - Biomembr. 1461, 47–57 (1999).

200.        Samet, D. & Barenholz, Y. Characterization of acidic and neutral sphingomyelinase activities in crude extracts of HL-60 cells. Chem. Phys. Lipids 102, 65–77 (1999).

201.        Zuidam, N. J., Barenholz, Y. & Minsky, A. Chiral DNA packaging in DNA-cationic liposome assemblies. FEBS Lett. 457, 419–422 (1999).

202.        Diminsky, D., Moav, N., Gorecki, M. & Barenholz, Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18, 3–17 (1999).

203.        Naslavsky, N. et al. Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J. Biol. Chem. 274, 20763–20771 (1999).

204.        Zuidam, N. J., Hirsch-Lerner, D., Margulies, S. & Barenholz, Y. Lamellarity of cationic liposomes and mode of preparation of lipoplexes affect transfection efficiency. Biochim. Biophys. Acta - Biomembr. 1419, 207–220 (1999).

205.        Vardy, D. et al. Topical amphotericin B for cutaneous leishmaniasis [8]. Arch. Dermatol. 135, 856–857 (1999).

206.        Bandak, S., Ramu, A., Barenholz, Y. & Gabizon, A. Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Pharm. Res. 16, 841–846 (1999).

207.        Zuidam, N. J. & Barenholz, Y. Characterization of DNA-lipid complexes commonly used for gene delivery. Int. J. Pharm. 183, 43–46 (1999).

208.        Babai, I., Samira, S., Barenholz, Y., Zakay-Rones, Z. & Kedar, E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine 17, 1239–1250 (1999).

209.        Babai, I., Samira, S., Barenholz, Y., Zakay-Rones, Z. & Kedar, E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine 17, 1223–1238 (1999).

210.        Cabanes, A. et al. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin. Cancer Res. 5, 687–693 (1999).

211.        Grant, G. J., Barenholz, Y., Piskoun, B., Bolotin, E. M. & Turndorf, H. A novel liposomal bupivacaine formulation using an ammonium sulfate gradient. Reg. Anesth. Pain Med. 24, 42 (1999).

212.        Tirosh, O., Katzhendler, J., Barenholz, Y. & Kohen, R. Low-Density Lipoprotein Oxidation and Its Prevention by Amidothionophosphate Antioxidants. Antioxidants Redox Signal. 1, 325–338 (1999).

213.        Korablyov, V., Zimran, A. & Barenholz, Y. Cerebroside-β-glucosidase encapsulation in liposomes for Gaucher’s disease treatment revisited. Pharm. Res. 16, 466–469 (1999).

214.        Bangham, A. D. et al. Letter to the editor (multiple letters). J. Liposome Res. 9, 155–179 (1999).

215.        Barenholz, Y. & Gatt, S. Preface. Chem. Phys. Lipids 102, 1–2 (1999).

216.        Barenholz, Y. & Thompson, T. E. Sphingomyelin: Biophysical aspects. Chem. Phys. Lipids 102, 29–34 (1999).

217.        Tirosh, O., Katzhendler, Y., Barenholz, Y. & Kohen, R. Antioxidant activity of amidothionophosphates. Methods in Enzymology vol. 299 293–300 (1999).

218.        Clerc, S. & Barenholz, Y. A quantitative model for using acridine orange as a transmembrane pH gradient probe. Anal. Biochem. 259, 104–111 (1998).

219.        Gabizon, A., Goren, D., Cohen, R. & Barenholz, Y. Development of liposomal anthracyclines: From basics to clinical applications. J. Control. Release 53, 275–279 (1998).

220.        Hirsch-Lerner, D. & Barenholz, Y. Probing DNA-cationic lipid interactions with the fluorophore trimethylammonium diphenyl-hexatriene (TMADPH). Biochim. Biophys. Acta - Biomembr. 1370, 17–30 (1998).

221.        Zuidam, N. J. & Barenholz, Y. Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim. Biophys. Acta - Biomembr. 1368, 115–128 (1998).

222.        Samuni, A. M., Crommelin, D. J. A., Zuidam, N. J. & Barenholz, Y. Differential scanning calorimetry. A tool to assess physical and chemical alterations in liposomes. J. Therm. Anal. Calorim. 51, 37–48 (1998).

223.        Tirosh, O., Barenholz, Y., Katzhendler, J. & Priev, A. Hydration of polyethylene glycol-grafted liposomes. Biophys. J. 74, 1371–1379 (1998).

224.        Moses, A. E. et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin. Infect. Dis. 26, 1430–1433 (1998).

225.        Zuidam, N. J. & Barenholz, Y. Erratum: Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin’ (Biochim. Biophys. Acta 1329 (1997) (211-222) PII: 20005273697001107). Biochim. Biophys. Acta - Biomembr. 1372, 151 (1998).

226.        Frankenburg, S., Glick, D., Klaus, S. & Barenholz, Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob. Agents Chemother. 42, 3092–3096 (1998).

227.        Kedar, E., Palgi, O., Golod, G., Babai, I. & Barenholz, Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-α show improved pharmacokinetics and biological activity and reduced toxicity in mice. J. Immunother. 20, 180–193 (1997).

228.        Samuni, A. M., Barenholz, Y., Crommelin, D. J. A. & Zuidam, N. J. γ-irradiation damage to liposomes differing in composition and their protection by nitroxides. Free Radic. Biol. Med. 23, 972–979 (1997).

229.        Zuidam, N. J. & Barenholz, Y. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin. Biochim. Biophys. Acta - Biomembr. 1329, 211–222 (1997).

230.        Tirosh, O., Kohen, R., Katzhendler, J., Alon, A. & Barenholz, Y. Oxidative stress effect on the integrity of lipid bilayers is modulated by cholesterol level of bilayers. Chem. Phys. Lipids 87, 17–22 (1997).

231.        Diminsky, D., Schirmbeck, R., Reimann, J. & Barenholz, Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): Composition, structure and immunogenicity. Vaccine 15, 637–647 (1997).

232.        Bar, L. K., Barenholz, Y. & Thompson, T. E. Effect of sphingomyelin composition on the phase structure of phosphatidylcholine- phingomyelin bilayers. Biochemistry 36, 2507–2516 (1997).

233.        Eckstein, M., Barenholz, Y., Bar, L. K. & Segal, E. Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice. Vaccine 15, 220–224 (1997).

234.        Felgner, P. L. et al. Nomenclature for synthetic gene delivery systems. Hum. Gene Ther. 8, 511–512 (1997).

235.        Samuni, A. M. & Barenholz, Y. Stable nitroxide radicals protect lipid acyl chains from radiation damage. Free Radic. Biol. Med. 22, 1165–1174 (1997).

236.        Tirosh, O., Kohen, R., Katzhendler, J., Gorodetsky, R. & Barenholz, Y. Novel synthetic phospholipid protects lipid bilayers against oxidation damage: Role of hydration layer and bound water. J. Chem. Soc. Perkin Trans. 2 383–389 (1997) doi:10.1039/a601955b.

237.        Glick, D. & Barenholz, Y. IgG immunoglobulins induce activation of the sphingomyelin cycle in HL-60 cells. FEBS Lett. 394, 237–240 (1996).

238.        Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I. & Barenholz, Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: Pharmacokinetics and biodistribution in tumor-bearing mice. Pharm. Res. 13, 861–868 (1996).

239.        Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I. & Barenholz, Y. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm. Res. 13, 352–359 (1996).

240.        Pop, E. et al. Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. Pharm. Res. 13, 469–475 (1996).

241.        Pop, E. et al. Derivatives of dexanabinol. I. Water-soluble salts of glycinate esters. Pharm. Res. 13, 62–69 (1996).

242.        Barenholz, Y., Cohen, T., Haas, E. & Ottolenghi, M. Lateral organization of pyrene-labeled lipids in bilayers as determined from the deviation from equilibrium between pyrene monomers and excimers. J. Biol. Chem. 271, 3085–3090 (1996).

243.        Barenholz, Y., Bolotin, E., Cohen, R. & Gabizon, A. Sterically stabilized doxorubicin loaded liposomes (DOX-SLTM): From basics to the clinics. Phosphorus, Sulfur Silicon Relat. Elem. 109, 293–296 (1996).

244.        Tirosh, O., Katzhendler, Y., Barenholz, Y., Ginsburg, I. & Kohen, R. Antioxidant properties of amidothionophosphates: Novel antioxidant molecules. Free Radic. Biol. Med. 20, 421–432 (1996).

245.        Zomber, G., Bogin, E. & Barenholz, Y. Effect of I.V. injection of small unilamellar liposomes of egg phosphatidylcholine on cholesterol in plasma and erythrocytes, serum enzymes and liver function in dogs. J. Liposome Res. 6, 455–477 (1996).

246.        Diminsky, D., Reimann, Z. J., Schirmbeck, R. & Barenholz, Y. Structural and functional characterization of liposomal recombinant hepatitis B vaccine. J. Liposome Res. 6, 289–304 (1996).

247.        Clerc, S. & Barenholz, Y. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. BBA - Biomembr. 1240, 257–265 (1995).

248.        Zuidam, N. J., Gouw, H. K. M. E., Barenholz, Y. & Crommelin, D. J. A. Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. BBA - Biomembr. 1240, 101–110 (1995).

249.        Lasic, D. D. et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. BBA - Biomembr. 1239, 145–156 (1995).

250.        Böhm, W. et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J. Immunol. 155, 3313–3321 (1995).

251.        Levy, M. Y., Polacheck, I., Barenholz, Y. & Benita, S. Efficacy Evaluation of a Novel Submicron Miconazole Emulsion in a Murine Cryptococcosis Model. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 12, 223–230 (1995).

252.        Bergers, J. J., Bloois, L. V, Barenholz, Y. & Crommelin, D. J. A. Conformational changes of myoglobin upon interaction with negatively-charged phospholipid vesicles. J. Liposome Res. 5, 311–326 (1995).

253.        Shmeeda, H., Petkova, D. & Barenholz, Y. Cholesterol distribution in rat heart myocytes. Am. J. Physiol. - Hear. Circ. Physiol. 268, H759–H766 (1995).

254.        Barenholz, Y. & Cohen, R. Rational design of amphiphile-based drug carriers and sterically stabilized carriers. J. Liposome Res. 5, 905–932 (1995).

255.        Adler, A. et al. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: Clinical and immunobiological effects. Cancer Biother. 10, 293–306 (1995).

256.        Haran, G., Cohen, R., Bar, L. K. & Barenholz, Y. Erratum: Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases (Biochim. Biophys. Acta 1151 (1993) 201-215 (BBAMEM 76069)). Biochim. Biophys. Acta - Biomembr. 1190, 197 (1994).

257.        Bolotin, E. M. et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposome Res. 4, 455–479 (1994).

258.        Caplan, S., Gallily, R. & Barenholz, Y. Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor. Cancer Immunol. Immunother. 39, 27–33 (1994).

259.        Kedar, E., Rutkowski, Y., Braun, E., Emanuel, N. & Barenholz, Y. Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes. J. Immunother. 16, 47–59 (1994).

260.        Shmeeda, H., Petkova, D. & Barenholz, Y. Cholesterol homeostasis in cultures of rat heart myocytes: Relationship to cellular hypertrophy. Am. J. Physiol. - Hear. Circ. Physiol. 267, H1689–H1697 (1994).

261.        Kedar, E., Braun, E., Rutkowski, Y., Emanuel, N. & Barenholz, Y. Delivery of Cytokines by Liposomes. II. Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes: Immunomodulatory and Anti-Tumor Activity in Mice. J. Immunother. 16, 115–124 (1994).

262.        Gabizon, A. et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. (Madr). 33, 779–786 (1994).

263.        Eldor, A. et al. A chronic hypercoagulable state and life-long platelet activation in beta thalassemia major. Southeast Asian J. Trop. Med. Public Health 24 Suppl 1, 92–95 (1993).

264.        Haran, G., Cohen, R., Bar, L. K. & Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. BBA - Biomembr. 1151, 201–215 (1993).

265.        Levy, M. Y., Polacheck, I., Barenholz, Y. & Benita, S. Efficacy evaluation of a novel submicron amphotericin b emulsion in murine candidiasis. Med. Mycol. 31, 207–218 (1993).

266.        Gorodetsky, R., Amselem, S. & Barenholz, Y. Trace element analysis of liposomal formulations by diagnostic X-ray fluorescence spectrometry (DXS). Chem. Phys. Lipids 64, 31–34 (1993).

267.        Borenstain, V. & Barenholz, Y. Characterization of liposomes and other lipid assemblies by multiprobe fluorescence polarization. Chem. Phys. Lipids 64, 117–127 (1993).

268.        Amselem, S., Cohen, R. & Barenholz, Y. In vitro tests to predict in vivo performance of liposomal dosage forms. Chem. Phys. Lipids 64, 219–237 (1993).

269.        Barenholz, Y. Preface. Chem. Phys. Lipids 64, 1–2 (1993).

270.        Bach, D., Miller, I. R. & Barenholz, Y. Thermotropic behavior of phosphatidylcholine-glucosyl ceramide mixtures: Effects of phospholipid acyl chain composition and interaction with water. Biophys. Chem. 47, 77–86 (1993).

271.        Engelhard, D. et al. Disseminated visceral fusariosis treated with amphotericin b-phospholipid complex. Leuk. Lymphoma 9, 385–392 (1993).

272.        Barenholz, Y., Pal, R. & Wagner, R. R. [22] Metabolic Labeling of Viral Membrane Lipids by Fluorescent Fatty Acids: Studying Virus Fusion with Target Membranes. Methods in Enzymology vol. 220 288–312 (1993).

273.        Barenholz, Y. et al. Stability of liposomal doxorubicin formulations: Problems and prospects. Med. Res. Rev. 13, 449–491 (1993).

274.        Gabizon, A. A., Barenholz, Y. & Bialer, M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 10, 703–708 (1993).

275.        Yashar, V. B., Barenholz, Y., Hy‐Am, E., Rachmilewitz, E. A. & Eldor, A. Phosphatidylserine in the outer leaflet of red blood cells from β‐thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am. J. Hematol. 44, 63–65 (1993).

276.        Gregoriadis, G., Wang, Z., Barenholz, Y. & Francis, M. J. Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory. Immunology 80, 535–540 (1993).

277.        Lasic, D. D., Frederik, P. M., Stuart, M. C. A., Barenholz, Y. & McIntosh, T. J. Gelation of liposome interior A novel method for drug encapsulation. FEBS Lett. 312, 255–258 (1992).

278.        Horowitz, A. T., Barenholz, Y. & Gabizon, A. A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. BBA - Biomembr. 1109, 203–209 (1992).

279.        Kalmanzon, E., Zlotkin, E., Cohen, R. & Barenholz, Y. Liposomes as a model for the study of the mechanism of fish toxicity of sodium dodecyl sulfate in sea water. BBA - Biomembr. 1103, 148–156 (1992).

280.        Goetschel, R., Barenholz, Y. & Bar, R. Microbial conversions in a liposomal medium. Part 2: Cholesterol oxidation by Rhodococcus erythropolis. Enzyme Microb. Technol. 14, 390–395 (1992).

281.        Amselem, S. et al. Preparation and characterization of liposomal doxorubicin for human use. J. Liposome Res. 2, 93–123 (1992).

282.        Gabizon, A. et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64, 1125–1132 (1991).

283.        Ben-Yashar, V. & Barenholz, Y. Characterization of the core and surface of human plasma lipoproteins. A study based on the use of five fluorophores. Chem. Phys. Lipids 60, 1–14 (1991).

284.        Barenholz, Y., Cohen, T., Korenstein, R. & Ottolenghi, M. Organization and dynamics of pyrene and pyrene lipids in intact lipid bilayers. Photo-induced charge transfer processes. Biophys. J. 60, 110–124 (1991).

285.        Goren, D., Gabizon, A. & Barenholz, Y. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. BBA - Biomembr. 1029, 285–294 (1990).

286.        Almog, S. et al. States of Aggregation and Phase Transformations in Mixtures of Phosphatidylcholine and Octyl Glucoside. Biochemistry 29, 4582–4592 (1990).

287.        Gabizon, A. et al. Preclinical and clinical experience with a doxorubicin-liposome preparation. J. Liposome Res. 1, 491–502 (1990).

288.        Amselem, S., Gabizon, A. & Barenholz, Y. Optimization and upscaling of doxorubicin‐containing liposomes for clinical use. J. Pharm. Sci. 79, 1045–1052 (1990).

289.        Ben-Yashar, V. & Barenholz, Y. The interaction of cholesterol and cholest-4-en-3-one with dipalmitoylphosphatidylcholine. Comparison based on the use of three fluorophores. BBA - Biomembr. 985, 271–278 (1989).

290.        Barenholz, Y. et al. The metastability of glucosyl ceramide in aqueous phase: effect of hydration and phosphatidylcholines of various chain length. Thermochim. Acta 148, 355–363 (1989).

291.        Bar, L. K., Chong, P. L.-G., Barenholz, Y. & Thompson, T. E. Spontaneous transfer between phospholipid bilayers of dehydroergosterol, a fluorescent cholesterol analog. BBA - Biomembr. 983, 109–112 (1989).

292.        Druckmann, S., Gabizon, A. & Barenholz, Y. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: Implications for pharmacokinetic studies. BBA - Biomembr. 980, 381–384 (1989).

293.        Gabizon, A. et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur. J. Cancer Clin. Oncol. 25, 1795–1803 (1989).

294.        Amselem, S., Gabizon, A. & Barenholz, Y. Evaluation of a new extrusion device for the production of stable oligolamellar liposomes in a liter scale. J. Liposome Res. 1, 287–301 (1989).

295.        Gabizon, A., Goren, D. & Barenholz, Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models. Isr. J. Med. Sci. 24, 512–517 (1988).

296.        Schroeder, F., Nemecz, G., Barenholz, Y., Gratton, E. & Thompson, T. E. Cholestatrienol time resolved fluorescence in phosphatidylcholine bilayers. in Time-Resolved Laser Spectroscopy in Biochemistry 1988 (ed. J.R., L.) vol. 909 457–465 (SPIE, 1988).

297.        Pal, R., Barenholz, Y. & Wagner, R. R. Pyrene Phospholipid as a Biological Fluorescent Probe for Studying Fusion of Virus Membrane with Liposomes. Biochemistry 27, 30–36 (1988).

298.        Schroeder, F., Nemecz, G., Gratton, E., Barenholz, Y. & Thompson, T. E. Fluorescence properties of cholestatrienol in phosphatidylcholine bilayer vesicles. Biophys. Chem. 32, 57–72 (1988).

299.        Yashar, V. B., Menashe, M., Biltonen, R. L., Johnson, M. L. & Barenholz, Y. Interaction of trans-parinaric acid with phosphatidylcholine bilayers: comparison with the effect of other fluorophores. BBA - Biomembr. 904, 117–124 (1987).

300.        Pal, R., Barenholz, Y. & Wagner, R. R. Vesicular stomatitis virus membrane proteins and their interactions with lipid bilayers. BBA - Rev. Biomembr. 906, 175–193 (1987).

301.        Bar, L. K., Barenholz, Y. & Thompson, T. E. Dependence on Phospholipid Composition of the Fraction of Cholesterol Undergoing Spontaneous Exchange between Small Unilamellar Vesicles. Biochemistry 26, 5460–5465 (1987).

302.        Hresko, R. C., Sugár, I. P., Barenholz, Y. & Thompson, T. E. The lateral distribution of pyrene-labeled sphingomyelin and glucosylceramide in phosphatidylcholine bilayers. Biophys. J. 51, 725–733 (1987).

303.        Schroeder, F., Barenholz, Y., Gratton, E. & Thompson, T. E. A Fluorescence Study of Dehydroergosterol in Phosphatidylcholine Bilayer Vesicles. Biochemistry 26, 2441–2448 (1987).

304.        Amselem, S., Barenholz, Y., Loyter, A., Nir, S. & Lichtenberg, D. Fusion of Sendai virus with negatively charged liposomes as studied by pyrene-labelled phospholipid liposomes. BBA - Biomembr. 860, 301–313 (1986).

305.        Yechiel, E., Henis, Y. I. & Barenholz, Y. Aging of rat heart fibroblasts: relationship between lipid composition, membrane organization and biological properties. BBA - Biomembr. 859, 95–104 (1986).

306.        Yechiel, E. & Barenholz, Y. Cultured heart cell reaggregates: a model for studying relationships between aging and lipid composition. BBA - Biomembr. 859, 105–109 (1986).

307.        Samuni, A., Chong, P. L.-G., Barenholz, Y. & Thompson, T. E. Physical and Chemical Modifications of Adriamycin:Lron Complex by Phospholipid Bilayers. Cancer Res. 46, 594–599 (1986).

308.        Bar, L. K., Barenholz, Y. & Thompson, T. E. Fraction of Cholesterol Undergoing Spontaneous Exchange between Small Unilamellar Phosphatidylcholine Vesicles. Biochemistry 25, 6701–6705 (1986).

309.        Moscona-Amir, E., Henis, Y. I., Sokolovsky, M., Yechiel, E. & Barenholz, Y. Role of Lipids in Age-Related Changes in the Properties of Muscarinic Receptors in Cultured Rat Heart Myocytes. Biochemistry 25, 8118–8124 (1986).

310.        Hresko, R. C., Sugár, I. P., Barenholz, Y. & Thompson, T. E. Lateral Distribution of a Pyrene-Labeled Phosphatidylcholine in Phosphatidylcholine Bilayers: Fluorescence Phase and Modulation Study. Biochemistry 25, 3813–3823 (1986).

311.        Chejanovsky, N., Zakai, N., Loyter, A., Amselem, S. & Barenholz, Y. Membrane Vesicles Containing the Sendai Virus Binding Glycoprotein, but Not the Viral Fusion Protein, Fuse with Phosphatidylserine Liposomes at Low pH. Biochemistry 25, 4810–4817 (1986).

312.        Gabizon, A., Meshorer, A. & Barenholz, Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 77, 459–469 (1986).

313.        Wiener, J. R., Pal, R., Barenholz, Y. & Wagner, R. R. Effect of the Vesicular Stomatitis Virus Matrix Protein on the Lateral Organization of Lipid Bilayers Containing Phosphatidylglycerol: Use of Fluorescent Phospholipid Analogues†. Biochemistry 24, 7651–7658 (1985).

314.        Yechiel, E., Barenholz, Y. & Henis, Y. I. Lateral mobility and organization of phospholipids and proteins in rat myocyte membranes. J. Biol. Chem. 260, 9132–9136 (1985).

315.        Yechiel, E. & Barenholz, Y. Relationships between membrane lipid composition and biological properties of rat myocytes. J. Biol. Chem. 260, 9123–9131 (1985).

316.        Amselem, S., Loyter, A., Lichtenberg, D. & Barenholz, Y. The interaction of Sendai virus with negatively charged liposomes: virus-induced lysis of carboxyfluorescein-loaded small unilamellar vesicles. BBA - Biomembr. 820, 1–10 (1985).

317.        Levin, I. W., Thompson, T. E., Barenholz, Y. & Huang, C. Two Types of Hydrocarbon Chain Interdigitation in Sphingomyelin Bilayers. Biochemistry 24, 6282–6286 (1985).

318.        Brown, R. E., Stephenson, F. A., Markello, T., Barenholz, Y. & Thompson, T. E. Properties of a specific glycolipid transfer protein from bovine brain. Chem. Phys. Lipids 38, 79–93 (1985).

319.        Reizer, J., Grossowicz, N. & Barenholz, Y. The effect of growth temperature on the thermotropic behavior of the membranes of a thermophilic Bacillus. Composition-structure-function relationships. BBA - Biomembr. 815, 268–280 (1985).

320.        Gabizon, A., Meshorer, A. & Barenholz, Y. A comparative study of toxicities of free and liposome-associated adriamycin (ADM). Proc. Am. Assoc. Cancer Res. VOL. 26, (1985).

321.        Pal, R., Petri  Jr., W. A., Ben-Yashar, V., Barenholz, Y. & Wagner, R. R. Characterization of the Fluorophore 4-Heptadecyl-7-hydroxycoumarin: A Probe for the Head-Group Region of Lipid Bilayers and Biological Membranes. Biochemistry 24, 573–581 (1985).

322.        Hresko, R. C., Markello, T. C., Barenholz, Y. & Thompson, T. E. Purification and spectroscopic properties of pyrene fatty acids. Chem. Phys. Lipids 38, 263–273 (1985).

323.        Gabizon, A., Goren, D., Fuks, Z., Meshorer, A. & Barenholz, Y. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br. J. Cancer 51, 681–689 (1985).

324.        Cohen, R. & Barenholz, Y. Characterization of the association of Electrophorus electricus acetylcholinesterase with sphingomyelin liposomes. Relevance to collagen-sphingomyelin interactions. BBA - Biomembr. 778, 94–104 (1984).

325.        Wong, M., Brown, R. E., Thompson, T. E. & Barenholz, Y. Glycolipid Transfer Protein from Bovine Brain. Biochemistry 23, 6498–6505 (1984).

326.        Cohen, R., Barenholz, Y., Gatt, S. & Dagan, A. Preparation and characterization of well defined d-erythro sphingomyelins. Chem. Phys. Lipids 35, 371–384 (1984).

327.        Wong, M., Brown, R., Barenholz, Y. & Thompson, T. E. Glycolipid transfer protein from bovine brain. Fed. Proc. 43, (1984).

328.        Gabizon, A. et al. Enhancement of Adriamycin Delivery to Liver Metastatic Cells with Increased Tumoricidal Effect Using Liposomes as Drug Carriers. Cancer Res. 43, 4730–4735 (1983).

329.        Pal, R., Petri Jr., W. A., Barenholz, Y. & Wagner, R. R. Lipid and protein contributions to the membrane surface potential of vesicular stomatitis virus probed by a fluorescent pH indicator, 4-heptadecyl-7-hydroxycoumarin. BBA - Biomembr. 729, 185–192 (1983).

330.        Frank, A., Lichtenberg, D., Thompson, T. E. & Barenholz, Y. Spontaneous Transfer of Sphingomyelin between Phospholipid Bilayers. Biochemistry 22, 5647–5651 (1983).

331.        Felgner, P. L., Thompson, T. E., Barenholz, Y. & Lichtenberg, D. Kinetics of Transfer of Gangliosides from Their Micelles to Dipalmitoylphosphatidylcholine Vesicles. Biochemistry 22, 1670–1674 (1983).

332.        Pal, R., Wiener, J. R., Barenholz, Y. & Wagner, R. R. Influence of the Membrane Glycoprotein and Cholesterol of Vesicular Stomatitis Virus on the Dynamics of Viral and Model Membranes: Fluorescence Studies. Biochemistry 22, 3624–3630 (1983).

333.        Bkaily, G., Sperelakis, N., Elishalom, Y. & Barenholz, Y. Effect of Na+- or Ca2+-filled liposomes on electrical activity of cultured heart cells. Am. J. Physiol. - Hear. Circ. Physiol. 14, H756–H761 (1983).

334.        Michaelson, D. M., Barkai, G. & Barenholz, Y. Asymmetry of lipid organization in cholinergic synaptic vesicle membranes. Biochem. J. 211, 155–162 (1983).

335.        Wiener, J. R., Pal, R., Barenholz, Y. & Wagner, R. R. Influence of the Peripheral Matrix Protein of Vesicular Stomatitis Virus on the Membrane Dynamics of Mixed Phospholipid Vesicles: Fluorescence Studies. Biochemistry 22, 2162–2170 (1983).

336.        Barenholz, Y. et al. Thermotropic Behavior of Aqueous Dispersions of Glucosylceramide-Dipalmitoylphosphatidylcholine Mixtures. Biochemistry 22, 3497–3501 (1983).

337.        Correa-Freire, M. C., Barenholz, Y. & Thompson, T. E. Glucocerebroside Transfer between Phosphatidylcholine Bilayers. Biochemistry 21, 1244–1248 (1982).

338.        Neumann, S., Korenstein, R., Barenholz, Y. & Ottolenghi, M. Photoinduced Charge Separation and Recombination in Exciplex Systems in Lipid Bilayer Vesicles. Isr. J. Chem. 22, 125–132 (1982).

339.        Barenholz, Y. & Gatt, S. Sphingomyelin: Metabolism, chemical synthesis, chemical and physical properties. New Comprehensive Biochemistry vol. 4 129–177 (1982).

340.        Goll, J., Carlson, F. D., Barenholz, Y., Litman, B. J. & Thompson, T. E. Photon correlation spectroscopic study of the size distribution of phospholipid vesicles. Biophys. J. 38, 7–13 (1982).

341.        Yedgar, S., Cohen, R., Gatt, S. & Barenholz, Y. Hydrolysis of monomolecular layers of synthetic sphingomyelins by sphingomyelinase of staphylococcus aureus. Biochem. J. 201, 597–603 (1982).

342.        Litman, B. J. & Barenholz, Y. Fluorescent Probe: Diphenylhexatriene. Methods in Enzymology vol. 81 678–685 (1982).

343.        Dagan, A., Barenholz, Y. & Gatt, S. Synthesis of fluorescent derivatives of lipids and their potential pharmacological application. Isr. J. Med. Sci. 18, 558 (1982).

344.        Pal, R., Barenholz, Y. & Wagner, R. R. Pardaxin, a hydrophobic toxin of the red sea flatfish, disassembles the intact membrane of vesicular stomatitis virus. J. Biol. Chem. 256, 10209–10212 (1981).

345.        Barenholz, Y., Yechiel, E., Cohen, R. & Deckelbaum, R. J. Importance of cholesterol-phospholipid interaction in determining dynamics of normal and abetalipoproteinemia red blood cell membrane. Cell Biophys. 3, 115–126 (1981).

346.        Lentz, B. R., Hoechli, M. & Barenholz, Y. Acyl Chain Order and Lateral Domain Formation in Mixed Phosphatidylcholine-Sphingomyelin Multilamellar and Unilamellar Vesicles. Biochemistry 20, 6803–6809 (1981).

347.        Feigner, P. L., Freire, E., Barenholz, Y. & Thompson, T. E. Asymmetric Incorporation of Trisialoganglioside into Dipalmitoylphosphatidylcholine Vesicles. Biochemistry 20, 2168–2172 (1981).

348.        Freire, E. et al. Effect of Surface Curvature on Stability, Thermodynamic Behavior, and Osmotic Activity of Dipalmitoylphosphatidylcholine Single Lamellar Vesicles. Biochemistry 20, 3462–3467 (1981).

349.        Estep, T. N. et al. Thermal Behavior of Stearoylsphingomyelin-Cholesterol Dispersions. Biochemistry 20, 7115–7118 (1981).

350.        Gatt, S. et al. Assay of Enzymes of Lipid Metabolism with Colored and Fluorescent Derivatives of Natural Lipids. Methods in Enzymology vol. 72 351–375 (1981).

351.        Petri, W. A., Pal, R., Wagner, R. R. & Barenholz, Y. Fluorescence Studies of Dipalmitoylphosphatidylcholine Vesicles Reconstituted with the Glycoprotein of Vesicular Stomatitis Virus. Biochemistry 20, 2796–2800 (1981).

352.        Petri Jr., W., Pal, R., Barenholz, Y. & Wagner, R. R. Fluorescence anisotropy of a fatty acid covalently linked in vivo to the glycoprotein of vesicular stomatitis virus. J. Biol. Chem. 256, 2625–2627 (1981).

353.        Pal, R., Barenholz, Y. & Wagner, R. R. Transcription of vesicular stomatitis virus activated by Pardaxin, a fish toxin that permeabilizes the virion membrane. J. Virol. 39, 641–645 (1981).

354.        Pal, R., Barenholz, Y. & Wagner, R. R. Depletion and Exchange of Cholesterol from the Membrane of Vesicular Stomatitis Virus by Interaction with Serum Lipoproteins or Poly(vinylpyrrolidone) Complexed with Bovine Serum Albumin. Biochemistry 20, 530–539 (1981).

355.        Gatt, S., Gazit, B. & Barenholz, Y. Effect of bile salts on the hydrolysis of gangliosides, glycoproteins and neuraminyl-lactose by the neuraminidase of Clostridium perfringens. Biochem. J. 193, 267–273 (1981).

356.        Freire, E., Bach, D., Correa-Freire, M., Miller, I. & Barenholz, Y. Calorimetric Investigation of the Complex Phase Behavior of Glucocerebroside Dispersions. Biochemistry 19, 3662–3665 (1980).

357.        Pal, R., Barenholz, Y. & Wagner, R. R. Effect of cholesterol concentration on organization of viral and vesicle membranes. Probed by accessibility to cholesterol oxidase. J. Biol. Chem. 255, 5802–5806 (1980).

358.        Cestaro, B., Barenholz, Y. & Gatt, S. Hydrolysis of Di-and Trisialo Gangliosides in Micellar and Liposomal Dispersion by Bacterial Neuraminidases. Biochemistry 19, 615–619 (1980).

359.        Barenholz, Y. & Thompson, T. E. Sphingomyelins in bilayers and biological membranes. Biochim. Biophys. Acta - Biomembr. 604, 129–158 (1980).

360.        Estep, T. N. et al. Evidence for metastability in stearoylphingomyelin bilayers. Biochemistry 19, 20–24 (1980).

361.        Gatt, S., Gazit, B., Cestaro, B. & Barenholz, Y. Hydrolysis of gangliosides in micellar and liposomal dispersion by bacterial neuraminidases. Adv. Exp. Med. Biol. 125, 137–146 (1980).

362.        Gatt, S., Dinur, T. & Barenholz, Y. A fluorometric determination of sphingomyelinase by use of fluorescent derivatives of sphingomyelin, and its application to diagnosis of Niemann-Pick disease. Clin. Chem. 26, 93–96 (1980).

363.        Barenholz, Y. et al. Characterization of micellar and liposomal dispersions of gangliosides and phospholipids. Adv. Exp. Med. Biol. 125, 105–123 (1980).

364.        Deckelbaum, R. J., Eisenberg, S., Fainaru, M., Barenholz, Y. & Olivecrona, T. In vitro production of human plasma low density lipoprotein-like particles. A model for very low density lipoprotein catabolism. J. Biol. Chem. 254, 6079–6087 (1979).

365.        Borochov, H., Shinitzky, M. & Barenholz, Y. Sphingomyelin phase transition in the sheep erythrocyte membrane. Cell Biochem. Biophys. 1, 219–228 (1979).

366.        Estep, T. N., Mountcastle, D. B., Barenholz, Y., Biltonen, R. L. & Thompson, T. E. Thermal Behavior of Synthetic Sphingomyelin-Cholesterol Dispersions. Biochemistry 18, 2112–2117 (1979).

367.        Correa-Freire, M. C., Freire, E., Barenholz, Y., Biltonen, R. L. & Thompson, T. E. Thermotropic Behavior of Monoglucocerebroside-Dipalmitoylphosphatidylcholine Multilamellar Liposomes. Biochemistry 18, 442–445 (1979).

368.        Kapitulnik, J., Tshershedsky, M. & Barenholz, Y. Fluidity of the rat liver microsomal membrane: Increase at birth. Science (80-. ). 206, 843–844 (1979).

369.        Shinitzky, M. & Barenholz, Y. Fluidity parameters of lipid regions determined by fluorescence polarization. BBA - Rev. Biomembr. 515, 367–394 (1978).

370.        Patzer, E. J., Moore, N. F., Barenholz, Y., Shaw, J. M. & Wagner, R. R. Lipid organization of the membrane of vesicular stomatitis virus. J. Biol. Chem. 253, 4544–4550 (1978).

371.        Schmidt, C. F., Barenholz, Y., Huang, C. & Thompson, T. E. Monolayer coupling in sphingomyelin bilayer systems. Nature 271, 775–777 (1978).

372.        Patzer, E. J., Wagner, R. R. & Barenholz, Y. Cholesterol oxidase as a probe for studying membrane organisation [32]. Nature 274, 394–395 (1978).

373.        Goldberg, R., Barenholz, Y. & Gatt, S. Synthesis of trinitrophenylaminolauric acid and the use of its glyceryl esters for assaying lipase by a spectrophotometric procedure. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 531, 237–241 (1978).

374.        Barenholz, Y., Erulkar, S. D., Meiri, H. & Rahamimoff, R. Increase in quantal transmitter release by calcium- and sodium-containing phosphatidylcholine liposomes [proceedings]. J. Physiol. 284, 65P-66P (1978).

375.        Gatt, S., Dinur, T. & Barenholz, Y. A spectrophotometric method for determination of sphingomyelinase. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 530, 503–507 (1978).

376.        Cohen, R. & Barenholz, Y. Correlation between the thermotropic behavior of sphingomyelin liposomes and sphingomyelin hydrolysis by sphingomyelinase of Staphylococcus aureus. BBA - Biomembr. 509, 181–187 (1978).

377.        Rahamimoff, R., Meiri, H., Erulkar, S. D. & Barenholz, Y. Changes in transmitter release induced by ion-containing liposomes. Proc. Natl. Acad. Sci. U. S. A. 75, 5214–5216 (1978).

378.        Barenholz, Y., Gafni, A. & Eisenberg, S. Apparent microviscosity of intact and post-lipolysis (‘remnant’) very low density lipoprotein particles. Chem. Phys. Lipids 21, 179–185 (1978).

379.        Cestaro, B., Barenholz, Y. & Gatt, S. Hydrolysis by bacterial neuraminidases of gangliosides in form of micelle or liposome. Ital. J. Biochem. 27, 64–65 (1978).

380.        Barenholz, Y., Patzer, E. J., Moore, N. F. & Wagner, R. R. Cholesterol oxidase as a probe for studying membrane composition and organization. Adv. Exp. Med. Biol. 101, 45–56 (1978).

381.        Moore, N. F., Patzer, E. J., Wagner, R. R. & Barenholz, Y. Effect of Phospholipase C and Cholesterol Oxidase on Membrane Integrity, Microviscosity, and Infectivity of Vesicular Stomatitis Virus. Biochemistry 16, 4708–4715 (1977).

382.        Schmidt, C. F., Barenholz, Y., Huang, C. & Thompson, T. E. Phosphatidylcholine 13C-Labeled Carbonyls as a Probe of Bilayer Structure. Biochemistry 16, 3948–3954 (1977).

383.        Barenholz, Y. et al. A Simple Method for the Preparation of Homogeneous Phospholipid Vesicles. Biochemistry 16, 2806–2810 (1977).

384.        Schmidt, C. F., Barenholz, Y. & Thompson, T. E. A Nuclear Magnetic Resonance Study of Sphingomyelin in Bilayer Systems. Biochemistry 16, 2649–2656 (1977).

385.        Hertz, R. & Barenholz, Y. The relations between the composition of liposomes and their interaction with triton X-100. J. Colloid Interface Sci. 60, 188–200 (1977).

386.        Lentz, B. R., Barenholz, Y. & Thompson, T. E. Fluorescence Depolarization Studies of Phase Transitions and Fluidity in Phospholipid Bilayers. 1. Single Component Phosphatidylcholine Liposomes. Biochemistry 15, 4521–4528 (1976).

387.        Lentz, B. R., Barenholz, Y. & Thompson, T. E. Fluorescence Depolarization Studies of Phase Transitions and Fluidity in Phospholipid Bilayers. 2. Two-Component Phosphatidylcholine Liposomes. Biochemistry 15, 4529–4537 (1976).

388.        Barenholz, Y., Moore, N. F. & Wagner, R. R. Enveloped Viruses as Model Membrane Systems: Microviscosity of Vesicular Stomatitis Virus and Host Cell Membranes. Biochemistry 15, 3563–3570 (1976).

389.        Kutchai, H., Barenholz, Y., Ross, T. F. & Wermer, D. E. Developmental changes in plasma membrane fluidity in chick embryo heart. BBA - Biomembr. 436, 101–112 (1976).

390.        Stubbs, G. W., Litman, B. J. & Barenholz, Y. Microviscosity of the Hydrocarbon Region of the Bovine Retinal Rod Outer Segment Disk Membrane Determined by Fluorescent Probe Measurements. Biochemistry 15, 2766–2772 (1976).

391.        Barenholz, Y., Suurkuusk, J., Mountcastle, D., Thompson, T. E. & Biltonen, R. L. A Calorimetric Study of the Thermotropic Behavior of Aqueous Dispersions of Natural and Synthetic Sphingomyelins. Biochemistry 15, 2441–2447 (1976).

392.        Suurkuusk, J., Lentz, B. R., Barenholz, Y., Biltonen, R. L. & Thompson, T. E. A Calorimetric and Fluorescent Probe Study of the Gel-Liquid Crystalline Phase Transition in Small, Single-Lamellar Dipalmitoylphosphatidylcholine Vesicles. Biochemistry 15, 1393–1401 (1976).

393.        Moore, N. F., Barenholz, Y., McAllister, P. E. & Wagner, R. R. Comparative membrane microviscosity of fish and mammalian rhabdoviruses studied by fluorescence depolarization. J. Virol. 19, 275–278 (1976).

394.        Moore, N. F., Barenholz, Y. & Wagner, R. R. Microviscosity of togavirus membranes studied by fluorescence depolarization: influence of envelope proteins and the host cell. J. Virol. 19, 126–135 (1976).

395.        Litman, B. J. & Barenholz, Y. The optical activity of d-erythro-sphingomyelin and its contribution to the circular dichroism of sphingomyelin-containing systems. BBA - Biomembr. 394, 166–172 (1975).

396.        Quinn, P. J. & Barenholz, Y. A comparison of the activity of phosphatidylinositol phosphodiesterase against substrate in dispersions and as monolayers at the air water interface. Biochem. J. 149, 199–208 (1975).

397.        Hertz, R. & Barenholz, Y. Permeability and integrity properties of lecithin-sphingomyelin liposomes. Chem. Phys. Lipids 15, 138–156 (1975).

398.        Lentz, B. R., Barenholz, Y. & Thompson, T. E. A simple method for the synthesis of cholesterol esters in high yield. Chem. Phys. Lipids 15, 216–221 (1975).

399.        Barenholz, Y. & Gatt, S. [49] Separation of Sphingosine Bases by Chromatography on Columns of Silica Gel. Methods in Enzymology vol. 35 529–533 (1975).

400.        Barenholz, Y. & Gatt, S. [29] Acetyl coenzyme A: Long-chain base acetyltransferase from the microsomes of Hansenula ciferri. Methods in Enzymology vol. 35 242–247 (1975).

401.        Barenholz, Y. & Gatt, S. [30] Acetyl coenzyme A: Amine acetyltransferase from the soluble fraction of Hansenula ciferri. Methods in Enzymology vol. 35 247–253 (1975).

402.        Shinitzky, M. & Barenholz, Y. Dynamics of the hydrocarbon layer in liposomes of lecithin and sphingomyelin containing dicetylphosphate. J. Biol. Chem. 249, 2652–2657 (1974).

403.        Barenholz, Y., Edelman, I. & Shimon, G. Amine:acetyl coenzyme A acetyltransferase from the soluble fraction of Hansenula ciferri: Isolation and properties. BBA - Enzymol. 358, 262–274 (1974).

404.        Yedgar, S., Barenholz, Y. & Cooper, V. G. Molecular weight, shape and structure of mixed micelles of Triton X-100 and sphingomyelin. BBA - Biomembr. 363, 98–111 (1974).

405.        Cooper, V. G., Yedgar, S. & Barenholz, Y. Diffusion coefficients of mixed micelles of Triton X-100 and sphingomyelin and of sonicated sphingomyelin liposomes, measured by autocorrelation spectroscopy of Rayleigh scattered light. BBA - Biomembr. 363, 86–97 (1974).

406.        Barenholz, Y., Leffler, J. N. & Lefer, A. M. Detection by chemical methods of a myocardial depressant factor in plasma of animals in circulatory shock. Isr. J. Med. Sci. 9, 640–647 (1973).

407.        Hertz, R. & Barenholz, Y. Glucose release measurements from liposomes with an oxygen electrode. BBA - Biomembr. 330, 1–7 (1973).

408.        Barenholz, Y., Gadot, N., Valk, E. & Gatt, S. Identification of the enzymatic lesions responsible for the accumulation of acetylated sphingosine bases in the yeast Hansenula ciferri. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 306, 341–345 (1973).

409.        Gatt, S., Herzl, A. & Barenholz, Y. Hydrolysis of sphingomyelin liposomes by sphingomyelinase. FEBS Lett. 30, 281–285 (1973).

410.        Gatt, S. & Barenholz, Y. Enzymes of complex lipid metabolism. Annu. Rev. Biochem. 42, 61–90 (1973).

411.        Litvin, Y., Leffler, J. N., Barenholz, Y. & Lefer, A. M. Factors influencing the in vitro production of a myocardial depressant factor. Biochem. Med. 8, 199–212 (1973).

412.        Leffler, J. N., Litvin, Y., Barenholz, Y. & Lefer, A. M. Proteolysis in formation of a myocardial depressant factor during shock. Am. J. Physiol. 224, 824–831 (1973).

413.        Barenholz, Y. & Gatt, S. Long chain base-acetyl coenzyme A acetyltransferase from the microsomes of Hansenula ciferri. II. Kinetic properties. J. Biol. Chem. 247, 6834–6839 (1972).

414.        Barenholz, Y. & Gatt, S. Long chain base-acetyl coenzyme A acetyltransferase from the microsomes of Hansenula ciferri. I. Isolation and properties. J. Biol. Chem. 247, 6827–6833 (1972).

415.        Lefer, A. M. & Barenholz, Y. Pancreatic hydrolases and the formation of a myocardial depressant factor in shock. Am. J. Physiol. 223, 1103–1109 (1972).

416.        Barenholz, Y., Edelman, I. & Gatt, S. The metabolic basis for the accumulation of acetylated sphingosine bases in the yeast Hansenula ciferri. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 248, 458–465 (1971).

417.        Gatt, S. & Barenholz, Y. [26] Sphingomyelinase from rat brain. Methods in Enzymology vol. 14 144–149 (1969).

418.        Gatt, S. & Barenholz, Y. [31] Phospholipase A1 from rat brain, specific for α′ position of lecithin. EC 3.1.1.4 Phosphatide acyl-hydrolase. Methods in Enzymology vol. 14 167–170 (1969).

419.        Barenholz, Y. & Gatt, S. Acetylation of sphingosine bases and long-chain amines by cell-free preparations of Hansenula ciferri. Biochem. Biophys. Res. Commun. 35, 676–680 (1969).

420.        Gatt, S. & Barenholz, Y. Degradation of sphingosine bases by cell-free preparations. α-hydroxy palmitic acid, an intermediate of phytosphingosine degradation. Biochem. Biophys. Res. Commun. 32, 588–594 (1968).

421.        Barenholz, Y. & Gatt, S. Degradation of Sphingosine, Dihydrosphingosine, and Phytosphingosine in Rats. Biochemistry 7, 2603–2609 (1968).

422.        Barenholz, Y. & Gatt, S. Separation of sphingosine, dihydrosphingosine and phytosphingosine by chromatography on columns of silica gel. Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab. 152, 790–793 (1968).

423.        Barenholz, Y. & Gatt, S. The utilization and degradation of phytosphingosine by rat liver. Biochem. Biophys. Res. Commun. 27, 319–324 (1967).

424.        Gatt, S., Barenholz, Y. & Roitman, A. Isolation of rat brain lecithinase-A, specific for the α↑-position of lecithin. Biochem. Biophys. Res. Commun. 24, 169–172 (1966).

425.        Waknine-Grinberg, J. H., El-On, J., Barak, V., Barenholz, Y. & Golenser, J. The immunomodulatory effect of Sambucol on leishmanial and malarial infections. Planta Med. 75, 581–586 (2009).